Abstract: Compounds of formula: wherein: ALK represents an alkylene chain, W represents a group wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in treating cognitive disorders associated with cerebral aging or with neurodegenerative diseases.

Abstract: Compounds of formula (I): wherein: ALK represents an alkylene chain, W represents a group wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in the treatment of conditions associated with central histaminergic systems.

Abstract: Compounds of formula (I): wherein: ALK represents an alkylene chain, W represents a group wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in the treatment of conditions associated with central histaminergic systems.

Abstract: Compounds of formula (I): wherein: ALK represents an alkylene chain, W represents a group selected from wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in the treatment of cognitive and psycho-behavioural disorders associated with cerebral ageing, with neurodegenerative diseases or with cranial traumas and also in the treatment of mood disorders, of schizophrenia and of cognitive disorders associated therewith, of sleep disorders, of sleep-waking rhythm disorders, of attention-deficit hyperactivity syndrome or of obesity.

Abstract: Compounds of formula (I): wherein: ALK represents an alkylene chain, W represents a group selected from wherein R and R? are as defined in the description. Medicinal products containing the same which are useful in the treatment of cognitive and psycho-behavioural disorders associated with cerebral ageing, with neurodegenerative diseases or with cranial traumas and also in the treatment of mood disorders, of schizophrenia and of cognitive disorders associated therewith, of sleep disorders, of sleep-waking rhythm disorders, of attention-deficit hyperactivity syndrome or of obesity.

Abstract: A compound selected from those of formula (I): wherein m and n, which may be identical or different, each represent an integer from 0 to 2 inclusive, with the sum of the two integers being from 2 to 3 inclusive, p and q, which may be identical or different, each represent an integer from 0 to 2 inclusive, Alk represents an alkylene, alkenylene or alkynylene chain, X represents an oxygen atom, a sulphur atom or an —N(R)— group wherein R represents a hydrogen atom or an alkyl group, Y, Y? and W are as defined in the description, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful for treating conditions associated with central histaminergic systems.

Abstract: A compound selected from those of formula (I): wherein m and n, which may be identical or different, each represent an integer from 0 to 2 inclusive, with the sum of the two integers being from 2 to 3 inclusive, p and q, which may be identical or different, each represent an integer from 0 to 2 inclusive, Alk represents an alkylene, alkenylene or alkynylene chain, X represents an oxygen atom, a sulphur atom or an —N(R)— group wherein R represents a hydrogen atom or an alkyl group, Y, Y? and W are as defined in the description, its enantiomers, diastereoisomers, and addition salts thereof with one or more pharmaceutically acceptable acid or base. Medicinal products containing the same which are useful for treating conditions associated with central histaminergic systems.

Abstract: A compound selected from those of formula (I): 1

Abstract: A compound selected from those of formula (1): ##STR1## wherein W represents aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each being optionally substituted,R.sub.1 represents alkyl, alkenyl, alkynyl, aryl, cycloalkyl, arylalkyl, or cycloalkylalkyl, each being optionally substituted.R.sub.2 is as defined in the description,its isomers, and addition salts thereof with a pharmaceutically-acceptable acid or base, and medicinal products containing the same which are useful as anti-oxidation agents.

Abstract: New N-substituted cyclic amines of formula: ##STR1## wherein: X, R.sub.1, R.sub.2 and R are as defined in the description, their optical and geometric isomers and physiologically tolerable salts thereof. The compounds of the invention are powerful PDE4 inhibitors and can be used therapeutically.

Abstract: A compound of general formula (I): ##STR1## in which: R.sub.1 represents alkyl,X represents oxygen, --CHR'-- or --CR'.dbd.,R' is chosen from hydrogen and alkyl,R.sub.2 represents optionally substituted alkyl as is defined in the description, cycloalkyl or polycycloalkyl as are defined in the description,R.sub.3 represents hydrogen or hydroxyl,Alk represents alkylene, andY is as defined in the description,and medicinal products containing the same are useful as PDE IV inhibitors.

Abstract: A compound of formula (I): ##STR1## wherein: R.sub.1 represents unsubstituted or substituted cycloalkyl, phenyl, naphthyl, heterocyclic, alkyl or alkenyl,A represents a bond, oxygen, sulphur, a group ##STR2## a group ##STR3## or a group ##STR4## wherein Rc represents hydrogen, alkyl or cycloalkyl, R.sub.2 represents halogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, cycloalkyl, formyl, carboxy, alkylcarbonyl, cycloalkylcarbonyl, alkoxycarbonyl, cycloalkyloxycarbonyl, optionally substituted carbamoyl, optionally substituted amino, formylamino, cyano, optionally substituted amidino, hydroxyaminomethyl, amide oxime, hydrazono, or a group selected from: ##STR5## wherein R.sub.21, R.sub.22 and R.sub.23 are as defined in the description, R.sub.

Abstract: Novel bicyclic pyrimidine compounds for use as drugs and having formula (I). Said novel compounds and physiologically tolerable salts thereof may be used in therapeutics, particularly for suppressing tumour cell resistance to antineoplastic agents.

Abstract: The compounds are trisubstituted triazines and pyrimidines useful for the suppressing the resistance of tumour cells to anti-cancer agents and for suppressing the resistance of parasites to anti-parasitic agents.A compound disclosed is 2,4-diallylamino-6-{4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl) methylamino]piperidin-1-yl}-1,3,5-triazine.

Abstract: The compounds are 2,4-(optionally substituted amino)-6-substituted s.triazines, useful for suppressing the resistance of tumour cells to anti-cancer agents and for suppressing the resistance of parasites to anti-parasitic agents.A compound disclosed is 1-[4,6-bis(allylamino)-2-s-triazinyl]-4-[2,2-bis(p.fluorophenyl)ethylamino ]piperidine.

Abstract: The invention relates to the use, for obtaining medicaments that reverse resistance to anti-cancer and anti-malarial agents, of compounds of formula I: ##STR1## in which A is --CH-- or nitrogen,and B, R.sub.1, R.sub.2 and R.sub.3 are as defined in the description,and their physiologically tolerable acid addition salts.

Abstract: New pyrrolidone compounds of the formula: ##STR1## in which: R is OR", SR" or N (R.sub.3 R.sub.4)R' is optionally substituted alkyl or aryl, andthe carbon in the 5-position of the pyrrolidone ring, which is substituted by CH.sub.2 R has the R or S configuration.These new compounds and their physiologically tolerable salts may be used therapeutically especially in the treatment of asthenias, ischaemic syndromes and nervous disorders associated with normal or pathological ageing.

Abstract: New aminochromanol compounds of the formula: ##STR1## in which X is cyano, nitro, trifluoromethyl, alkoxycarbonyl, carbamido, dialkylcarbamido, aminosulfonyl, dialkylaminosulfonyl, alkylsulfonyl, alkylsulfonylamino or acyl;CH.sub.2 -R is attached (in the 5 position of the pyrrolidinone nucleus) to an R- or S-configured carbon atom, and R is:either OR' or SR' in which R' is hydrogen, (C.sub.1 -C.sub.10)-alkyl, (C.sub.1 -C.sub.5 -alkyl)-carbonyl or ##STR2## and physiologically tolerable acid addition salts thereof, in the case where R contains a basic function.These compounds and their physiologically tolerable salts can be used in therapeutics for the activation of potassium channels, especially in the treatment of disorders associated with abnormal smooth muscle contraction and in the cardiovascular, bronchopulmonary, digestive, urinary and uterine fields.

Abstract: New benzopyrrolidinone compounds, which can be used as medicaments and correspond to the formula ##STR1## in which: either: R.sub.1 and R.sub.2 together represent, with the bond of the etherocycle to which they are attached, an optionally substituted benzene nucleus and, simultaneously, R.sub.3 and R.sub.4 are hydrogen, (C.sub.1 -C.sub.4)alkyl or (C.sub.5 -C.sub.6)cycloalkyl;or:R.sub.1 is hydrogen, R.sub.4 is a single bond and R.sub.2 and R.sub.3 together represent, with the bond of the heterocycle to which they are bonded, an optionally substituted benzene nucleus; andA is a straight or branched hydrocarbon chain having from 2 to 6 carbon atoms that is optionally substituted by hydroxy;X is a single bond, oxygen or sulphur; andY is hydrogen, halogen or (C.sub.1 -C.sub.5)alkyl or alkoxy.These new compounds and the physiologically tolerable salts thereof can be used therapeutically, especially in the treatment of bronchospastic disorders and inflammations in the ENT area.

Abstract: Disubstituted polymethylene imines of the formula: ##STR1## in which: A is a straight or branched chain (C.sub.3 -C.sub.5) hydrocarbon containing radical optionally containing one or two double bond and optionally substituted by one or more hydroxy;n is zero, one or two;Z is oxygen or NH; andR is:either COR', in which R' is:(a) a straight or branched chain (C.sub.1 -C.sub.6), hydrocarbon containing radical, optionally containing one oxygen or sulfen or a double bond and optionally substituted by phenyl or substituted phenyl; or(b) phenyl, halophenyl, lower alkoxyphenyl, (di-or-tri-methylene) dioxyphenyl or;(c) furyl, thienyl, benzofuryl, benzothienyl or benzodioxannyl; or(d) ##STR2## in which R.sub.1 and R.sub.2 are hydrogen or lower alkyl or ##STR3## is a five or six membered heterocyclic radical which may contain an oxygen;or--SO.sub.2 R" in which R" is (C.sub.1 -C.sub.3) alkyl or phenyl.